Antiviral Therapy and HBV DNA Integration in Chronic Hepatitis B
Official title: Impact of Antiviral Therapy on Infection and Replication Derived Hepatitis B Virus DNA Integration
Funded at Baruch S. Blumberg Institute · NIH-11439278 · Data updated 2026-11-12
This project looks at how existing HBV drugs may influence the way HBV DNA becomes integrated into the liver cells’ DNA in people with chronic hepatitis B.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baruch S. Blumberg Institute NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $78,300 |
| NIH project number | 1R03AI201866-01 |
| Project ID | NIH-11439278 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic hepatitis B or those undergoing antiviral therapy who could participate in sample collection and analysis.
✕Less likely to help
Patients without access to liver tissue samples or who are not on antiviral therapy may not benefit directly.
What this research studies
If you have chronic hepatitis B, this study uses lab methods to see how antiviral medicines affect HBV DNA integration in patients’ liver cells. Researchers have updated a DNA sequencing approach to measure HBV integration more accurately and plan to compare how different drugs impact this process. The goal is to understand whether current therapies help prevent the virus from becoming part of the host genome, which is linked to liver cancer risk. The work could guide future treatment choices and spark new ideas for making cures more achievable.
Why it matters
Potential benefit: Better understanding of how antivirals affect HBV integration could lead to more effective therapies and lower cancer risk for people with chronic HBV.
How similar studies have gone: Previous work has shown HBV integration is linked to liver cancer, but this project tests how drugs influence that integration.
Where this research is happening
-
Baruch S. Blumberg Institute
Doylestown, United States Active
Researchers
- Principal investigator: Tang, Liudi — Baruch S. Blumberg Institute
- Study coordinator: Tang, Liudi
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.